Pier 88 Investment Partners LLC Decreases Position in Pyxis Oncology, Inc. (NASDAQ:PYXS)

Pier 88 Investment Partners LLC decreased its position in Pyxis Oncology, Inc. (NASDAQ:PYXS) by 18.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 98,590 shares of the company’s stock after selling 23,020 shares during the period. Pier 88 Investment Partners LLC’s holdings in Pyxis Oncology were worth $154,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Commonwealth Equity Services LLC lifted its position in shares of Pyxis Oncology by 61.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 26,250 shares of the company’s stock valued at $41,000 after buying an additional 10,000 shares during the last quarter. Intech Investment Management LLC bought a new stake in Pyxis Oncology in the 3rd quarter valued at about $55,000. MetLife Investment Management LLC lifted its holdings in Pyxis Oncology by 41.1% during the third quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock valued at $69,000 after purchasing an additional 5,484 shares during the last quarter. Sei Investments Co. bought a new position in Pyxis Oncology during the fourth quarter worth about $95,000. Finally, Public Employees Retirement System of Ohio purchased a new position in shares of Pyxis Oncology in the third quarter worth about $107,000. 39.09% of the stock is owned by institutional investors.

Analysts Set New Price Targets

PYXS has been the topic of a number of recent research reports. HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of Pyxis Oncology in a research note on Wednesday, March 19th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $8.00 price target on shares of Pyxis Oncology in a report on Wednesday, March 19th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $9.20.

Pyxis Oncology Trading Down 2.8 %

Pyxis Oncology stock opened at $1.06 on Monday. Pyxis Oncology, Inc. has a 1-year low of $0.99 and a 1-year high of $6.18. The firm has a market capitalization of $65.29 million, a PE ratio of -1.03 and a beta of 1.11. The firm’s 50 day simple moving average is $1.29 and its 200 day simple moving average is $2.26.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.01. The business had revenue of $16.15 million for the quarter. Research analysts forecast that Pyxis Oncology, Inc. will post -1.04 earnings per share for the current year.

Pyxis Oncology Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.